Strategic Alliances

Strategic Alliances

Tevogen’s next generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance with the goal of overcoming mutational capacity of cancer cells and viruses.

Tevogen is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.

The ongoing proof of concept clinical trial of company’s investigational precision T cell therapy (TVGN-489) for treatment of elderly and high-risk COVID-19 patients is expected to conclude in July 2022. The trial has reached the fourth and final dose level, no dose limiting toxicities or treatment-related adverse events, including Cytokine Release Syndrome (CRS), have been observed to date in any of the dose cohorts.

We believe the perspective and expertise afforded by strategic collaborations to be fundamental in successful introduction of our lead product TVGN-489.

For collaboration inquiries please contact sadiq.khan@tevogen.com

Corporate Overview

September 9th, 2022

Kindly fill out the form below to download the presentation.

Please contact us with collaboration inquiries at:
sadiq.khan@tevogen.com

© 2021 Tevogen Bio. All Rights Reserved.